Plasmapp (Youbong Lim, CEO) announced on the 12th that it had passed the preliminary review for listing at the KOSDAQ Market Headquarters of the Korea Exchange on the 11th. The company aims to be listed on the KOSDAQ market in October this year.

Established in 2015, Plasmapp has been rapidly growing in the global medical device market based on Bio Plasma technology, focusing on Plasma Medical Device Low-Temperature Sterilization Solution (STERLINK) and Plasma Implant Regenerative Solution (ACTILINK). It is also expanding its business into the healthcare industry through a new business of Plasma Biostimulation Therapy Solution (STIMLINK).

Plasmapp possesses core technologies related to bio plasma, including plasma inactivation and plasma activation. This technology is a key technology that increases sterilization efficiency by directly injecting sterilizing agents and solves the problem of surface performance degradation of implants to increase bioabsorption rates. Based on its major technological capabilities in sterilization, Plasmapp has shortened the existing sterilization time (from 1 hour to 7 minutes), making it the fastest in the world, and secured price competitiveness (from 10 to 20 million won to 10 million won). Furthermore, based on major technological capabilities related to rehabilitation, Plasmapp has successfully entered the dental market and is expected to expand its application market to plastic surgery and dermatology, anticipating even higher growth in the future.

Based on these strengths, Plasmapp has secured a high market adoption rate in the global market. Since 2019, it has entered over 55 countries including the United States, Europe, and Japan. Its revenue has also been rapidly increasing, from approximately 2.5 billion won in 2019 to approximately 6.4 billion won last year, and it is expected to achieve about three times the revenue growth compared to last year.

Furthermore, last November, the company became the first non-U.S. company to obtain FDA certification. In addition, it has been selected as a prospective unicorn by the Ministry of SMEs and Startups, one of the top 100 SMEs, and an innovative medical device company, proving its excellent technological competitiveness.

Youbong Lim, CEO of Plasmapp, expressed his pleasure at successfully passing the preliminary review, the first step toward listing on the KOSDAQ market, saying, "After all preparations are completed, we plan to submit a securities registration statement and proceed with the formal listing process."

Source: NEWSPIM ( www.newspim.com )